Search

Displaying results 1201 - 1210 of 1764 in total
  1. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

  2. Drug

    3-Acetylpyridine Adenine Dinucleotide

    go.drugbank.com/drugs/DB03363
    Experimental

    (Dorland, 27th ed)

  3. Drug

    Polysorbate 80

    go.drugbank.com/drugs/DB11063
    ApprovedInvestigational

    Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it

  4. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

  5. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188]

  6. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.

  7. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

  8. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. … December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease,[L45275] and the EMA

  9. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

  10. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    [A173842] Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery,

    Products: MIDOLAM 5MG/1ML IM/IV/REKTAL ÇÖZELTI IÇEREN AMPUL, OZASED 2 mg/ml Lösung zum Einnehmen im Einzeldosisbehältnis